LEVOTHYROXINE SODIUM

Post-LOE

levothyroxine sodium

Piramal Pharma

ANDAINTRAVENOUSPOWDER

Approved

Jun 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

LEVOTHYROXINE SODIUM (levothyroxine sodium) by Piramal Pharma is 12. Approved for myxedema coma. First approved in 2016.

Drug data last refreshed 18h ago

Mechanism of Action

12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor…

Worked on LEVOTHYROXINE SODIUM at Piramal Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (3)

NCT04037748Phase 1Completed

Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form

Started Jun 2019

72 enrolled

Healthy

NCT03094416Phase 4Completed

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

Started Jul 2018

66 enrolled

Hypothyroidism;Postablative

NCT01916304Phase 2Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Started Jul 2013

101 enrolled

Hypothyroidism

LEVOTHYROXINE SODIUM

Mechanism of Action

Indications (1)

Clinical Trials (3)